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CC BY-NC-ND license (http://creativBackground/Purpose: Four types of antivenom are used to treat snakebites by the six species
of venomous snakes native to Taiwan. Research into antivenom use in Taiwan and its out-
comes, as well as the utility of current Taiwan Poison Control Center guidelines for antivenom
use, has been limited. We aimed to provide increased understanding by investigating the treat-
ment and outcomes of patients treated for snakebite in Taiwan.
Methods: On the basis of data collected from the 2009 Taiwan National Health Insurance data-
base, patients with snakebites were identified and categorized into two sets of groups accord-
ing to types of antivenom administered. The relationships between antivenom types, dosage
and the variables of antibiotic use, surgical intervention, acute respiratory failure acute, renal
failure, antivenom-related allergic reaction, mortality, need for hospital admission, and length
of hospitalization were analyzed by multivariate logistic regression and the KruskaleWallis
test.
Results: The majority of patients were successfully treated by administration of 1 vial of an-
tivenom and discharged without complications. However, patients treated for neurotoxic-
type venom snakebite required administration of larger doses of antivenom and > 30% required
surgical intervention, particularly those treated for Chinese cobra snakebite. Approximately
10% of patients were administered two types of antivenom.
Conclusion: The results partially support Taiwan Poison Control Center guidelines for treating
the hemorrhagic-type venom snakebite. However, deficit in the guidelines for treatment of
neurotoxic-type venom snakebite is obvious and new guidelines for treatment of neurotoxic-
type venom snakebite and diagnosis should be developed.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Six medically important venomous snake species are native
to Taiwan. Antivenoms have been developed since the
1960s, and have been available to treat snakebites by
several of these species. However, only w15% of snakebite
cases are treated with antivenom, with the majority being
treated with herbal medicine.1 In the 1980s, horse immu-
noglobulin G-derived antivenom made with several types of
F(ab0)2 fragments were developed by the Vaccine Center,
Center for Disease Control, Taiwan.2e4 These included a
bivalent antivenom against the hemorrhagic venom (FH
antivenom) of the green habu (Viridovipera stejnegeri) and
the Taiwan habu (Protobothrops mucrosquamatus); a
bivalent antivenom against the neurotoxic venom (FN an-
tivenom) of the Taiwan banded krait (Bungarus multi-
cinctus) and the Chinese cobra (Naja atra); and an
antivenom against the hemorrhagic venom of the hundred-
pace snake (FA antivenom; Deinagkistrodon acutus). An
antivenom against the mixed type venom of the Russell’s
viper (Daboia russelii) was not developed until mid-2008.
Among these types of venom, neurotoxic venom causes
respiratory distress, diplopia, dysarthria, and extremity
paralysis. Although these neurologic symptoms result from
circulation of the venom of the Chinese cobra to a lesser
extent than that of the Taiwan banded krait, circulation of
the venom of the Chinese cobra may cause direct tissue
damage. Hemorrhagic venom causes local tissue swelling
that may progress to the development of compartment
syndrome. Therefore, regardless of whether antivenom
against hemorrhagic or neurotoxic venom is required, sur-
gical intervention, such as debridement, fasciotomy, or
graft, may also be needed.
The current treatment guidelines for antivenom usage
recommended by the Taiwan Poison Control Center (TPCC)
are based mainly on expert opinion and the results of in vitro
animal study.5 However, the research into the utility of these
guidelines and antivenom use in general has been limited.
Only one report conducted by a TPCC-affiliated hospital has
concluded that the TPCC guidelines for treating venomous
snakebites are useful.6 Moreover, even this one report raised
concerns regarding antivenom dosage discrepancies among
different groups of doctors within the same hospital in their
use of the same type of antivenom. An additional research
difficulty is that snakebite data in Taiwan are limited,1 with
most derived from single-hospital-based case series that also
reported discrepancies in antivenom dosage.7 Thus, an
investigation of current snakebite antivenom usage in
Taiwan may provide a better understanding of its advantages
and disadvantages, and yield data with which to develop
recommendations for revision of the TPCC antivenom
guidelines. We aimed to provide increased understanding by
investigating the treatment and outcomes of patients
treated for snakebite in Taiwan.
Methods
Study population
Taiwan launched a single-payer National Health Insurance
(NHI) program on March 1, 1995. According to the NHIBureau, in 2009, the percentage of NHI coverage of the
population surpassed 96% and the percentage of NHI-
cooperating medical facilities reached 95%.8,9 The NHI
maintains a database that contains registration files, claims
for reimbursement, and data regarding outpatient visits,
hospital admissions, disease diagnosis, prescriptions, pro-
cedures, interventions, and vital status for the entire
insured population. After scrambling patient identification
numbers to preserve patient privacy, the data are provided
to scientists in Taiwan for research purposes. As these data
are collected from patients nationwide, they are suitable
for epidemiological research and have been used widely in
academic studies.10
The NHI database assigns a code to each drug and pro-
cedure. By tracing the antivenom drug codes for FH anti-
venom (drug code: J000006212), FN antivenom (drug code:
J000009212), and FA antivenom (drug code: J000010209)
stored in the 2009 NHI database, we were able to retrieve
data regarding the cases treated by these types of anti-
venom in 2009. By using additional data extracted from the
2009 NHI database, we were able to link several comput-
erized administrative data claim sets to establish the lon-
gitudinal medical history of each beneficiary and the
outcomes of treatment for snakebite.
We began our analysis by categorizing the patients
administered antivenom for green habu and Taiwan habu
snakebite into the FH group, patients administered anti-
venom for Chinese cobra and Taiwan banded krait snake-
bite into the FN group, patients administered antivenom
for the hundred-pace snake into the FA group, patients
administered antivenom for Russell’s viper snakebite into
the FDrs group, and patients administered more than one
type of antivenom in a single episode into the mixed
group. As antivenom against Russell’s viper was not
available until mid-2008, the FDrs group was not included
in the analysis.
Variables examined
Data regarding patient antibiotic use; surgical in-
terventions, including debridement (procedure codes: 8622
and 8628), fasciotomy (procedure codes: 8212, 8235, 8314,
and 8344), and graft (procedure codes: 8661, 8662, 8669,
8670, 8672, 8382, 8663, 8673, and 8674); acute respiratory
failure requiring use of mechanical ventilation; acute renal
failure requiring hemodialysis; mortality; hospital admis-
sion; and length of hospitalization were collected. To es-
timate the rate of antivenom-related allergy occurrence,
we defined patients who experienced an antivenom-related
allergic reaction as those who had been administered
diphenhydramine and hydrocortisone along with anti-
venom, either as a pretreatment to prevent allergic reac-
tion or as treatment for an active antivenom-related
allergic reaction.
Statistical analysis
Continuous variables were expressed as mean  SD,
whereas the categorical variables were indicated as fre-
quency (%). For univariate analysis between groups, we
used the Student t test for continuous variables, the c2
Table 1 Clinical characteristics of patients with snake-
bites in Taiwan in 2009.
FH group
n Z 658
FN group
n Z 157
FA group
n Z 6
Mixed
group
n Z 71
Allergy* 31 (4.7) 11 (7.0) 0 6 (8.5)
No antibiotics* 119 (18.1) 37 (23.6) 4 (66.7) 10 (14.1)
Antibiotic*
Penicillin 152 (23.1) 49 (31.2) 1 (16.7) 50 (70.4)
Cephalosporin 430 (65.3) 90 (57.3) 1 (16.7) 18 (25.4)
Aminoglycoside 154 (23.4) 41 (26.1) 0 0
Quinolone 9 (1.4) 7 (4.5) 0 10 (14.1)
674 C.-C. Lin et al.test for categorical variables, and odds ratios (OR) for
expression of strength of association on categorical vari-
ables. Variables found to be statistically significant in the
univariate analysis were selected as candidates for the
subsequent multivariable analysis. Multivariate logistic
regression was performed to identify the effect of each
variable on the need for hospitalization and the length of
hospitalization. The KruskaleWallis test was performed to
identify the existence of significant differences between
different groups. All analyses were performed using SAS
statistical software version 9.2 (SAS Institute, Cary,
NC, USA). A p value < 0.05 was considered statistically
significant.Other 31 (4.7) 7 (4.5) 0 0
Surgical intervention
Debridement 12 12 0 0
Fasciotomy 13 15 0 0
Grafting 9 17 0 0
Other 18 4 0 0
Total* 52 (7.9) 48 (30.6) 0 0
*Data are presented as n (%).
FA Z patients administered antivenom for hundred-pace
snakebite; FH Z patients administered antivenom for green
habu or Taiwan habu snakebite; FN Z patients administered
antivenom for Chinese cobra or Taiwan banded krait snakebite;
Mixed: patients administered more than one type of antivenom.
Table 2 Logistic regression analysis of the effect of
selected variables on hospital admission in the FH and FN
groups.
Variable OR 95% CI* p
Age (y)
< 16 1 d d
16e45 0.975 0.354e2.690 0.427
45e65 0.713 0.263e1.934 0.2982
> 65 0.738 0.266e2.052 0.4563
Male sex 0.743 0.518e1.067 0.1073
Antibiotic
use (yes)
5.043 3.023e8.413 < 0.0001
Allergic reaction
(yes)
1.980 0.946e4.145 0.0698
Antivenom dosage
of > 1 vial (yes)
1.321 1.216e1.436 < 0.0001
Referral (yes) 4.526 2.628e7.795 < 0.0001
FN group (yes) 0.865 0.555e1.348 0.5204
*CI Z confidence interval; FH Z patients administered anti-
venom for green habu or Taiwan habu snakebite; FNZ patients
administered antivenom for Chinese cobra or Taiwan banded
krait snakebite; OR Z odds ratio.Results
Data regarding 892 snakebite incidents were extracted
from the 2009 NHI database. Because the FA group had only
six patients and the mixed group was not eligible for dosage
analysis, only the FH and FN groups were subjected to
complete analysis. Of the 658 patients in the FH group and
157 patients in the FN group, 52 (7.9%) and 48 (30.6%),
respectively, required surgical intervention. Statistical
analysis revealed that the FN group had undergone a
significantly greater (p < 0.0001) number of surgical in-
terventions. On the basis of our definition of antivenom-
related allergy, 48 patients (5.4%), including 31 (4.7%) in
the FH group and 11 (7.0%) in the FN group, experienced an
antivenom-related allergic reaction. Notably, no patients in
the FA group experienced an antivenom-related allergy
(Table 1). Of the 722 patients (80.9%) who underwent
antibiotic treatment, which included 478 who underwent
intravenous antibiotic treatment, the most commonly
administered antibiotic was cephalosporin. Two patients
each in the FH and FN groups experienced acute respiratory
failure requiring mechanical ventilation. Only one patient
in the FN group died.
Variables found to be significantly related to the need
for hospital admission were administration of antibiotics
[odds ratio (OR) 5.043, 95% confidence interval (CI)
3.023e8.413], administration of > 1 vial of antivenom (OR
1.321, 95% CI 1.216e1.413), and patient referral (OR 4.526,
95% CI 2.628e7.795; Table 2). Variables found to be
significantly related to extended duration of hospitalization
were surgical intervention, which was associated with a
6.82  0.99- and a 12.86  1.96-day increase in hospitali-
zation for the FH and FN groups, respectively (both
p < 0.0001); patient referral, which was associated with a
1.87  0.72- and a 3.91  1.70-day increase, respectively
(both p < 0.05); and administration of > 1 vial of anti-
venom, which was associated with a 0.27  0.09 (p < 0.01)-
and a 0.68  0.14 (p < 0.0001)-day increase, respectively,
for every additional vial administered beyond one (Table 3).
For further analysis of the condition of antivenom
usage, we divided the patients into three groups according
to hospital admission and discharge data. Group 1 con-
sisted of patients who had been directly discharged from
the emergency department without being hospitalized,
Group 2 of patients who had been admitted for hospitali-
zation but had not undergone surgical intervention, and
Group 3 of patients who had been admitted and undergonesurgical intervention. Group analysis revealed a stepwise
elevation in antivenom dosage from Group 1 to Group 2 to
Group 3 in both the FH and FN patients. Specifically, the
median antivenom dosage was 1 vial in both the FH and FN
groups in Group 1; 3 vials and 4.5 vials in the FH and FN
patients, respectively, in Group 2; and 3 vials and 8.5
vials in the FH and FN patients, respectively, in Group 3
(Table 4).
Table 3 Multiple regression analysis of the effect of selected variables on hospitalization length in the FH and FN groups.
Variable FH group
n Z 282
FN group
n Z 73
Estimate (d) SD* p Estimate (d) SD* p
Male sex 0.357 0.683 0.602 0.997 1.759 0.573
Age (y)
< 16 0.000 0.000
16e45 3.260 1.778 0.068 5.069 3.701 0.176
45e65 1.894 1.748 0.279 7.982 3.514 0.027
> 65 1.799 1.809 0.321 7.691 3.689 0.041
Referral (yes) 1.869 0.719 0.010 3.911 1.700 0.025
Surgical intervention (yes) 6.822 0.997 <0.0001 12.864 1.957 < 0.0001
Antibiotic use (yes) 0.356 1.310 0.786 0.542 3.142 0.864
Antivenom dosage of > 1 vial (yes) 0.266 0.088 0.003 0.680 0.135 < 0.0001
FH Z patients administered antivenom for green habu or Taiwan habu snakebite; FN Z patients administered antivenom for Chinese
cobra or Taiwan banded krait snakebite.
*SD Z standard deviation.
Table 4 Dosage of antivenom administered to patients with snakebite in 2009.
Group FH FN
Group 1
n Z 372
Group 2
n Z 253
Group 3
n Z 29
Group 1
n Z 80
Group 2
n Z 54
Group 3
n Z 20
Antivenom dosage (vials)
Median (IQR)
1.0 (1.0) 3.0 (2.0) 3.0 (4.0) 1.0 (1.0) 4.5 (6.0) 8.5 (6.0)
p* < 0.0001 < 0.0001
FH Z patients administered antivenom for green habu or Taiwan habu snakebite; FN Z patients administered antivenom for Chinese
cobra or Taiwan banded krait snakebite; Group 1 Z patients discharged without hospitalization; Group 2 Z patients hospitalized
without surgical intervention; Group 3 Z patients hospitalized with surgical intervention; IQR Z interquartile range.
* KruskaleWallis test.
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Our review of the data collected from the 2009 NHI
database revealed that treatment of patients with
snakebites in Taiwan with snake antivenom had generally
resulted in favorable outcomes, as indicated by the very
low mortality rate. Nevertheless, some degree of surgical
intervention had been required to treat some patients,
especially those who had been treated for Chinese cobra
snakebite and/or had been administered the highest doses
of antivenom. Moreover, almost 10% of patients had
been administered two types of antivenom as a result
of a diagnostic error. Such an error can result from diffi-
culty in differential diagnosis, as it is often difficult to
distinguish the tissue swelling resulting from Chinese
cobra snakebite from the tissue necrosis resulting
from the snakebite of other snakes in the early phase of
reaction to venom injection. Fortunately, Chinese cobra
venom can be accurately detected by enzyme-linked
immunoassay (the cobra detection kit), which may aid
physicians in distinguishing between neurotoxic and
hemorrhagic venom.11
The TPCC guideline for treatment of snakebites patients
only briefly described the symptomatic approach to diag-
nosing the culprit snake and then use of the correct anti-
venoms.12 The usage of the FH antivenom is recommend as1 vial antivenom to treat green habu (Viridovipera stejne-
geri) bitten patients and 1e4 vials to treat the Taiwan habu
(Protobothrops mucrosquamatus) bitten patients; while
from six to 10 vials FN antivenoms were recommend to
treat the Chinese cobra (Naja atra) bitten patients, and
1e4 vials to treat the Taiwan banded krait (Bungarus mul-
ticinctus) bitten patients. However, there is no clinical
symptom severity grading systems described to guide the
first antivenom dosage. There was no recommendation on
how and when to add the additional antivenom if initial
antivenom dose is not sufficient to treat the patients.
Although some authors suggested that treatment with FH
antivenom is administration of 1 vial every 2 hours until
clinical stabilization and a maximum administration of 4
vials in the FH group snakebites patients.6 As for tissue
necrosis, compartment syndrome due to limb swelling, the
TPCC guideline clearly stated surgical treatment is not
allowed unless deep tissue necrosis or compartment syn-
drome developed. Lacking these important recommenda-
tions may make doctors who treat snakebite patients on
their free evaluation of severity but not on the basis of
evidence medicine. One proof of this observation is Chen
et al6 report. In their report the patients who were treated
by surgeons received higher antivenom dosage than those
who were treated by emergency medicine physicians;
however, there was no difference in outcomes.
676 C.-C. Lin et al.Our results support the guidelines in the treatment of
Taiwan habu and green habu snakebite. However, several
smaller studies found that administration of 1 vial was
sufficient to treat the majority of patients.13e16 One single-
center study found that although patients who were
treated by surgeons had been administered a higher FH
antivenom dosage (5.9  4.2 vials) than those who were
treated by emergency medicine physicians (2.7  1.6 vials),
in accordance with the TPCC guideline both groups of pa-
tients experienced similar outcomes.6 Thus, the TPCC
guidelines for treatment with FH antivenom may need little
revision by adding severity grading systems to guide the
antivenom dosage.
The TPCC guidelines recommend administration of 6e10
vials of FN antivenom to treat Chinese cobra snakebite,
which is based on analysis of the neutralizing capacity of FN
antivenom against N. atra venom in mice.4 However, the
current study found that > 50% of patients required only 1
vial of FN antivenom to treat Chinese cobra snakebite.
Nevertheless, we also observed a wide range of variation in
the dosage of FN antivenom required, as had previous
studies.17,18 Such variation in dosage may be primarily
explained by the differing amount of venom injected at
each snakebite episode, a rebound in serum cobrotoxin
concentration after initial antivenom therapy may also play
a role. In one study, Hung et al19 observed that although
administration of 2 vials of FN antivenom initially resulted
in a rapid decrease in serum cobrotoxin concentration, a
subsequent rebound in serum cobrotoxin level required the
administration of additional vials of antivenom. The phe-
nomena underlying the rebound in serum cobrotoxin level
may be the high tissue affinity of cytotoxin for N. atra
venom and its capacity to increase N. atra distribution,20,21
decreasing the capacity of intravenously administered
circulating antivenom to completely neutralize the venom
in local tissue. The high tissue affinity of cytotoxin of N.
atra venom could lead to natural limitation of antivenom
effects in treating neurotoxic snakebite patients since it
may cause severe local tissue damage in the biting site. The
high tissue affinity of cytotoxin of N. atra venom also might
thus explain the wide range of FN antivenom dosage
required for treatment, as well as why patients who had
been administered the highest antivenom dosage had also
required surgical intervention. In our study, 30% of FN group
patients needed to receive surgical intervention, however,
up to 70% of patients in other studies required surgical
intervention17 also was observed. Wide ranges of patients
who need to receive surgical intervention in the cobra
biting patients existed in the different studies. Lack of the
severity grading system to evaluating the severity of snake
bites patients is one of the problems since a good severity
grading system can provide a more objective instrument for
the evaluation of severity and progression of envenomation
in patients with snakebite and thus guide the antivenom
usage.22 Another way to solve the above problem is to
develop a clinically useful tool that can measure venom
concentrations in the patient’s body. This kind of detection
kit can be combined with severity grading system to have a
better guide in antivenom use. Recently, the progress of
proteonomics may have a role in developing snakebites
severity assessment kits that may fulfill the gap we face
now.23 However, in the present time, we suggest that lessFN antivenom dosage could be used according to our pre-
sent study. Three vials of FN antivenom seems a reasonable
beginning dose if the symptoms are not mild. The additional
antivenom doses should be given based on symptom pro-
gression or venom detection results by using the venom
detection kit (the cobra detection kit).11 If the system
progresses quickly in a short time then an additional anti-
venom dose should be added. If progression of envenom-
ation is slow and negative result in the cobra detection kit
until 12 hours after treatment then no antivenom should be
added. Surgical interventions should be performed on an
evidence medicine base. As it is well documented in the
literature that antivenom is sufficient to treat snakebite
patients, surgical intervention should be reserved for the
last treatment method.24 The clinical signs and symptoms
of compartment syndrome (i.e., pain, numbness, change in
sensation, bruising, and paralysis) should be observed
closely. Compartment pressures measurement should be
performed serially to see if exceeding 30 mmHg.25 The
observation time should last at least 12 hours, because if
the compartment syndrome is allowed to continue for 12
hours or more, the incidence of permanent function loss is
high.26 Surgical interventions such as fasciotomy should be
performed only in the instance of true compartment syn-
drome documented by increased compartment pressures
that fail to respond to adequate and prompt administration
of antivenom.
We found the rate of possible antivenom allergic reac-
tion to be low, and possibly overestimated, as physicians
sometimes administer diphenhydramine and hydrocorti-
sone if patients test positive for an antivenom skin test
before antivenom administration. In one study that re-
ported a positive skin test rate of 42/130, Chen et al27
found that only one patient developed a skin rash thought
to be related to antivenom allergy and no patient experi-
enced an anaphylactic reaction following pretreatment
with diphenhydramine and hydrocortisone. Such findings
indicate that administration of FH and FN antivenom is a
relatively safe means of treating snakebites in Taiwan.
The major study limitation was our inability to identify
which snake species was responsible for the snakebites in
the FH or FN groups from the data collected from the 2009
database. However, because the symptoms and signs of
Taiwan habu and green habu snakebite are similar, this
limitation did not affect our antivenom analysis. By
contrast to those of the Chinese cobra snakebite, the
symptoms of the Taiwan banded krait snakebite are
neurotoxic manifestations, such as diplopia, dysarthria,
extremity paralysis, and respiratory distress, which do not
require surgical intervention. Thus, the patients who had
undergone surgical intervention in the FN group had clearly
been treated for Chinese cobra snakebite. As relatively
more data have been collected regarding patients treated
for Chinese cobra snakebite, future research should
endeavor to collect and analyze more data regarding pa-
tients treated for Taiwan banded krait snakebite.
Conclusively, w50% of patients can be successfully
treated for green habu or Taiwan habu snakebite or for
Chinese cobra, or Taiwan banded krait snakebite by
administration of 1 vial of FH antivenom or FN antivenom,
respectively. Use of the current syndromic approach to
snakebite diagnosis often does not allow for identification
Snakebite antivenom usage in Taiwan 677of the snake species responsible for a snakebite episode,
indicating the need for development of a more effective
approach. The TPCC guidelines for a snakebite patient’s
treatment could be revised to improve the treatment
result. Further investigation such as developing clinically
useful severity assessment tools should also endeavor to
improve treatments of snakebites.
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